Robert J. McCammon, M.D.


EDUCATION

 

1990-2003

Doctor of Medicine (May 2003)
University of Colorado Health Sciences Center
Denver, CO

Bachelor of Arts (1997), Economics, cum laude
Rice University
Houston, TX


PROFESSIONAL TRAINING:

 

2004-2008

Radiation Oncology Resident
University of Colorado Health Sciences Center
Aurora, CO

2003-2004

Transitional Year Intern
Presbyterian/St. Luke's Hospital
HealthOne
Denver, CO


MEDICAL LICENSE:

North Carolina, South Carolina


BOARD CERTIFICATION:

Radiation Oncology
American Board of Radiology


HONORS AND AWARDS:

 

2007

Chief Resident, Radiation Oncology
University of Colorado Health Sciences Center

2007

ASTRO Clinical Poster Award
ASTRO Annual Meeting

2005

Lead Resident, Radiation Oncology
University of Colorado Health Sciences Center

2003

Commencement Class Speaker, School of Medicine
University of Colorado Health Sciences Center


SCHOLARSHIPS AND SPECIAL TRAINING:

 

2009

Cyberknife Cranial and Extracranial Radiosurgery

2008

ABS Prostate Brachytherapy Fellowship

2002

Buckley Scholarship for Outstanding Student in
Basic Sciences, UCHSC

1995

Merit Scholarship, Rice University

1994

National Merit Scholar


PROFESSIONAL MEMBERSHIPS:

 

2004

American Society of Therapeutic Radiology and Oncology

2006

American Society of Clinical Oncology

2006

American Brachytherapy Society

1999

American Medical Association

1999

Colorado Medical Society

2002

Alpha Omega Alpha

2008

Mecklenburg County Medical Society


NATIONAL PRESENTATIONS:

1. McCammon RJ, Zeng C, Kavanagh B. Improved local control associated with stereotactic body radiation therapy (SBRT) dose escalation indicates a dose-response relationship. American Society for Therapeutic Radiology and Oncology (ASTRO) 2007 Annual Meeting, Los Angeles, CA. Poster Presentation

2. McCammon RJ, Finlayson T, Rabinovitch R. Survival Impact of Post-mastectomy Radiotherapy in T3N0 Invasive Ductal or Lobular Carcinoma of the Breast: A Surveillance, Epidemiology, and End-Results (SEER) Database Analysis. American Society of Clinical Oncology (ASCO) Breast Symposium 2007, San Francisco, CA. Poster Presentation

3. McCammon RJ, Furuya CE, Raben D, Song JI, Kane M, Gaspar LE, Chen C. The influence offluorine-18-flourodeoxyglucose positron emission tomography (FDGPET) on the clinical management of patients with head and neck cancer. American Society for Therapeutic Radiology and Oncology (ASTRO), Philadelphia, PA, November 5-9, 2006. Poster Presentation

4. Raben D, McCammon RJ, Newell S, Kavanagh B. Acute toxicity assessment of a single institution series of prostate cancer patients treated with pelvic intensity modulated radiation therapy with synchronous integrated boost to the prostate or prostate bed. American Society for Therapeutic Radiology and Oncology (ASTRO), Philadelphia, PA, November 5-9, 2006. Poster Viewing

5. McCammon RJ. Rocky Mountain Thoracic Oncology Symposium, Beaver Creek, CO, October 2004. Case Presentation


BOOK CHAPTERS AND PUBLICATIONS:

1. Pugh TJ, Ballonoff A, Rusthoven KE, McCammon R, Kavanagh B, Newman F, Rabinovitch R. Cardiac Mortality in Patients with Stage I and II Diffuse Large B-Cell Lymphoma Treated with and without Radiation: A Surveillance, Epidemiology, and End-Results Analysis. Int J Radiat Oncol Biol Phys 2009, June 8.

2. McCammon RJ, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D. Toxicity Assessment of Pelvic Intensity-Modulated Radiotherapy with Hypofractionated Simultaneous Integrated Boost to Prostate for Intermediate-and High-Risk Prostate Cancer. IJROBP 2009, April 11.

3. Schwer A, Kavanagh B, McCammon RJ, et al. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1352-7.

4. McCammon R, Schefter T, Gaspar L, Gravdahl D, Kavanagh B. Observation of A dose-control relationship with dose escalation with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):112-8.

5. McCammon R, Schwer A, Finlayson C, and Rabinovitch R. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: A Surveillance, Epidemiology, and End Results database analysis. Cancer 2008; August 15;115(4):683-89.

6. Schwer AL, Ballonoff A, McCammon RJ, Rusthoven K, et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):449-55.

7. Ballonoff A, Rusthoven K, Schwer A, McCammon RJ, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1465-71.

8. McCammon RJ, Furuya CE, Raben D, Song JI, Kane M, Gaspar LE, Chen C. The influence of fluorine-18-flourodeoxyglucose positron emission tomography (FDG-PET) on the clinical management of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2006;66(3):S184-185.

9. Ballenger's Otorhinolaryngology Head and Neck Surgery, B.C. Decker Publishers, 17th edition. McCammon RJ, Chen C, Suntha M, Raben D. Chemoradiation for Head and Neck Cancer: Current Approaches and Future Directions.

10. Web MD (www.webmd.com). McCammon RJ. Gynecologic Malignancies, 2005.

11. UpToDate (www.uptodate.com). McCammon RJ. Spinal Cord and Peripheral Nerve Toxicity from Radiation, 2005.

 

About Your Treatments

About Your Disease

Treatment Center Information

Get To Know Your Doctor

Quality Assurance